Dr. Franziska Thomas appointed as Associate Director to lead the way for innovative technology in the pharmaceutical and biotech sectors
Global Management Consultancy Arthur D. Little (ADL), today appointed Dr. Franziska Thomas as Associate Director to manage ADL’s Healthcare & Life Sciences Practice across Germany and Switzerland. Franziska and her team will be dedicated to supporting pharmaceutical and biotech companies in developing, marketing, and delivering innovative and highly effective drugs faster, and more effectively to patients through customized solutions.
In addition to the many years of strategic consulting experience in the pharmaceutical and biotech industries, Franziska has more than 12 years of professional experience at Boehringer Ingelheim and Rentschler Biopharma, where she focused on the development and market launch of biopharmaceuticals, including in oncology and rare diseases. She holds a degree in biochemistry and wrote her doctoral thesis at the ETH Zurich. She also worked as a post-doctoral fellow at Harvard University/Dana Farber Cancer Institute and authored publications in Cell and Science.
Dr. Franziska Thomas, at Arthur D. Little comments, "The pharmaceutical and biotech industry is on the cusp of the next major wave of innovations, which will bring personalized and potentially curative drugs for many serious or even rare diseases within reach. Being part of this progress and developing models on how we can make these innovations available to patients faster and more effectively, has always been a driving force for me. In an increasingly complex world, it is now important to work with our clients to develop tailored solutions that improve patients' lives over the long term, as well as fit the culture and size of the companies we work for. Arthur D. Little combines clear innovation management with outstanding transformation expertise and in-depth knowledge of the key megatrends. I am confident that we can help clients in the pharmaceutical and biotechnology industries to write a new chapter in drug development.”
Dr. Ulrica Sehlstedt, Global Head of Arthur D. Little Healthcare and Life Sciences Practice, adds, “We are very pleased to have Franziska and her team joining our growing global healthcare and life sciences team. Central Europe, with its high concentration of global pharmaceutical and biotech companies is a high priority region for us. Franziska brings expertise and experience that I am confident will serve our clients’ needs particularly well, both on a local and global basis. I am excited to collaborating with Franziska and her team and warmly welcome her to Arthur D. Little’s global healthcare and life sciences team.”
ADL has been working successfully in the German healthcare market for many years and has supported clients with innovative solutions and result-oriented transformation concepts. The newly acquired competencies in the fields of biotechnology and drug development form an integral part of ADL’s existing global Healthcare & Life Sciences activities across the US, Asia, Middle East and Europe.
Further information from:
Dr. Michael Siemer
Westend Medien GmbH
Tel: +49 (0)211 17520850
Fax: +49 (0)211 175208517